BBOT vs BBIO vs KYMR vs TPVG vs RVMD

For growth investors, BridgeBio Pharma, Inc.

(BBIO) is the stronger pick with 126. 3% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate BridgeBio Oncology Therapeutics Inc. (BBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Revolution Medicines, Inc.

(RVMD) delivered a total return of +382. 1%, compared to -22. 9% for BridgeBio Oncology Therapeutics Inc. (BBOT). Over 10 years, the gap is even starker: RVMD returned +390. 7% versus BBOT's -24. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.

(TPVG) is the lower-risk stock at 0. 77β versus BridgeBio Pharma, Inc. 's 1. 21β — meaning BBIO is approximately 57% more volatile than TPVG relative to the S&P 500. On balance sheet safety, BridgeBio Oncology Therapeutics Inc. (BBOT) carries a lower debt/equity ratio of 1% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BridgeBio Pharma, Inc.

(BBIO) is pulling ahead at 126. 3% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: TriplePoint Venture Growth BDC Corp. grew EPS 48. 8% year-over-year, compared to -1034. 8% for BridgeBio Oncology Therapeutics Inc.. Over a 3-year CAGR, BBIO leads at 86. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BBOT: 175.

7% to $21. 67.

In this comparison, TPVG (17.

1% yield) pays a dividend. BBOT, BBIO, KYMR, RVMD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77), 17. 1% yield). Both have compounded well over 10 years (TPVG: +91. 2%, BBIO: +144. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BBOT (Healthcare) and BBIO (Healthcare) and KYMR (Healthcare) and TPVG (Financial Services) and RVMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BBOT is a small-cap quality compounder stock; BBIO is a mid-cap high-growth stock; KYMR is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; RVMD is a mid-cap quality compounder stock. TPVG pays a dividend while BBOT, BBIO, KYMR, RVMD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.